GALT Stock Forecast, Price Targets, Chart, Dividends & Analysis
Galectin Therapeutics Inc.
GALT 
NSC
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
1.37
USD
0.03
(2.24%)
Previous close: 1.34 Open: 1.35 Bid: 1.37 Ask: 1.52
52 week range
0.73 3.17
Mkt Cap: 85 M Avg Vol (90 Days): 204,961
Last updated: Sunday 15th June 2025
Metrics
Valuation
Returns
7 Day Return | 3.79% | |
1 Month Return | 3.79% | |
3 Month Return | -14.91% | |
1 Year Return | -47.71% | |
3 Year Return | 7.87% | |
5 Year Return | -52.60% | |
YTD Return | 6.20% |
Risk
Custom Beta One Year | 0.53 |
Custom Beta Three Years | 0.62 |
Beneish M Score | 0.00 |
Altman Z Score | -40.79 |
Financial Health
Technicals
RSI (14 Day) | 55.60 |
14 Day SMA ($) | 1.31 |
14 Day EMA ($) | 1.32 |
Money Flow Index | 46.80 |
Average True Range | 0.09 |
50 Day SMA ($) | 1.33 |
200 Day SMA ($) | 1.85 |
ADX | 15.97 |
MACD | 0.04 |
Growth
Peers
| Stock | Dividend | Market Cap (B) | PE | Price ($) |
|---|
Financials
GALT Income Statement
Annual
| Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | Dec-24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| AccretionOnPreferredStock | 229000.0 | 173000.0 | ||||||||
| AccruedPreferredStockDividends | 868000.0 | 741000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 | 120000.0 | 153000.0 |
| Basic EPS from continuing operations | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | |||||
| Basic EPS total | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | |||||
| Basic weighted shares outstanding | 24 M | 29 M | 36 M | 39 M | 52 M | 57 M | 59 M | 59 M | 60 M | 62 M |
| Diluted EPS total | -0.88 | -0.76 | -0.49 | -0.38 | -0.39 | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 |
| Diluted normalized net income/share | -0.39 | -0.52 | -0.65 | -0.74 | -0.76 | |||||
| Diluted weighted shares outstanding | 23 M | 28 M | 33 M | 37 M | 52 M | 57 M | 59 M | 59 M | 60 M | 62 M |
| GainOnSaleOfSecurity | 138000.0 | 557000.0 | -432000.0 | 588000.0 | ||||||
| GeneralAndAdministrativeExpense | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M | 6 M | 6 M |
| Income before tax | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M | -38 M | -42 M |
| Interest income | 104000.0 | 45000.0 | 24000.0 | 38000.0 | 231000.0 | 66000.0 | 3000.0 | 52000.0 | 230000.0 | 338000.0 |
| InterestExpenseNonOperating | 12000.0 | 336000.0 | 87000.0 | 87000.0 | 489000.0 | 1 M | 3 M | 6 M | ||
| MiscOtherSpecialCharges | 138000.0 | 557000.0 | -3 M | 588000.0 | ||||||
| Net income from total operations | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M | -41 M | -47 M |
| NetIncomeCommonStockholders | -21 M | -22 M | -17 M | -15 M | -20 M | -24 M | -31 M | -39 M | -45 M | -47 M |
| NetIncomeContinuousOperations | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M | -41 M | -47 M |
| NetNonOperatingInterestIncomeExpense | 104000.0 | 45000.0 | 12000.0 | -298000.0 | 144000.0 | -21000.0 | -486000.0 | -981000.0 | 230000.0 | 338000.0 |
| Normalized income | -24 M | -41 M | ||||||||
| Operating income | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M | -38 M | -42 M |
| Operating income before depreciation (EBITDA) | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M | -41 M | -47 M |
| OperatingExpense | -20 M | -21 M | -16 M | -14 M | 13 M | 23 M | 30 M | 38 M | 38 M | 42 M |
| Other income net | -138000.0 | 557000.0 | 432000.0 | -588000.0 | ||||||
| OtherGandA | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M | 6 M | 6 M |
| OtherOperatingExpenses | 38 M | 42 M | ||||||||
| OtherunderPreferredStockDividend | 1 M | 914000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 | 120000.0 | 153000.0 |
| PreferredStockDividends | 1 M | 914000.0 | 1 M | 1 M | 7 M | 137000.0 | 171000.0 | 97000.0 | 120000.0 | 153000.0 |
| RentAndLandingFees | 7 M | 6 M | 5 M | 7 M | ||||||
| Research & development expense | 13 M | 15 M | 12 M | 6 M | 7 M | 18 M | 24 M | 32 M | 32 M | 37 M |
| ResearchExpense | 13 M | 15 M | 12 M | 6 M | 7 M | 18 M | 24 M | 32 M | 32 M | 37 M |
| SalariesAndWages | -4 M | -2 M | 2 M | 2 M | 2 M | |||||
| Selling Gen & administrative expense | 7 M | 6 M | 5 M | 7 M | 6 M | 5 M | 6 M | 7 M | 6 M | 6 M |
| Total Income available for interest expense (EBIT) | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -30 M | -38 M | -41 M | -42 M |
| Total common shares outstanding | 29 M | 34 M | 38 M | 46 M | 57 M | 57 M | 59 M | 59 M | 62 M | 63 M |
| Total net income | -20 M | -21 M | -16 M | -14 M | -13 M | -23 M | -31 M | -39 M | -41 M | -47 M |
| Total ordinary shares | 63 M | 63 M | 63 M | 63 M | 63 M | 63 M | 63 M | 63 M | 63 M | 63 M |
| TotalExpenses | -20 M | -21 M | -16 M | -14 M | 13 M | 23 M | 30 M | 38 M | 38 M | 42 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.